Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AuspiCiOus-dMMR: Anti-PD-1, capecitabine, and oxaliplatin for first-line treatment of dMMR esophagogastric cancer
2021-001181-38Phase 2Active
- Sponsor
- Academic Medical Center
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of retifanlimab in esophagogastric junction cancer, sponsored by Academic Medical Center. Primary endpoints: Interferon gamma expression in tumor microenvironment and Number of infiltrating cytotoxic T cells in tumor microenvironment. Started May 2021; status: active.
02
Drugs
retifanlimab
03
Conditions
esophagogastric junction cancer
Beyond the preview
Go deeper on 2021-001181-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001181-38.